Cargando…

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer

Detalles Bibliográficos
Autores principales:	Cox, Heather, Hames, Megan, Benrashid, Mona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017547/ https://www.ncbi.nlm.nih.gov/pubmed/27648346

Ejemplares similares

Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)

Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases
por: Kapoor, Anil, et al.
Publicado: (2019)

Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017)

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
por: Heidenreich, Axel, et al.
Publicado: (2019)

Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
por: Aprile, Carlo, et al.
Publicado: (2016)

Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2017)

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
por: Du, Yong, et al.
Publicado: (2017)

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223
por: Mukherji, Deborah, et al.
Publicado: (2014)

Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer
por: Makita, Kenji, et al.
Publicado: (2023)

Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Yoshida, Keisuke, et al.
Publicado: (2016)

Radium‐223 in Asian patients with castration‐resistant prostate cancer with symptomatic bone metastases: A single‐arm phase 3 study
por: Zhou, Tie, et al.
Publicado: (2020)

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2018)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: Vidal, Monica, et al.
Publicado: (2020)

Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases
por: Buscombe, John, et al.
Publicado: (2020)

Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
por: Prelaj, Arsela, et al.
Publicado: (2019)

Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
por: Gayed, Isis, et al.
Publicado: (2018)

Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
por: Nilsson, Sten
Publicado: (2016)

Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection
por: Den, Robert B., et al.
Publicado: (2019)

Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
por: Harrison, Michael R, et al.
Publicado: (2013)

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial
por: Morris, Michael J., et al.
Publicado: (2019)

Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation
por: Nguyen, Nghi C., et al.
Publicado: (2016)

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223
por: Roviello, Giandomenico, et al.
Publicado: (2018)

Editorial Comment: Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: dos Reis, Rodolfo Borges, et al.
Publicado: (2020)

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
por: van der Zande, Kim, et al.
Publicado: (2021)

Radium-223 Chloride: A New Treatment Option for Metastatic Castration-Resistant Prostate Carcinoma
por: Pinto, Álvaro, et al.
Publicado: (2012)

Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
por: Uemura, Hirotsugu, et al.
Publicado: (2019)

Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report
por: Dobashi, Masato, et al.
Publicado: (2020)

Administration of radium‐223 and the prognosis in Japanese bone metastatic castration‐resistant prostate cancer patients: A large database study
por: Kawahara, Takashi, et al.
Publicado: (2022)

Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report
por: McNamara, Megan A, et al.
Publicado: (2015)

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases
por: Sartor, O., et al.
Publicado: (2017)

Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer
por: Renzulli, Joseph F, et al.
Publicado: (2015)

Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial
por: Heidegger, Isabel, et al.
Publicado: (2018)

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
por: Fong, Lawrence, et al.
Publicado: (2021)

Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis
por: Zeng, Xiaohui, et al.
Publicado: (2022)

Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters
por: Shariftabrizi, Ahmad, et al.
Publicado: (2023)

Insights into the prognostic potential of total alkaline phosphatase in metastatic castration-resistant prostate cancer treated with radium-223
por: Viani, Gustavo
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lg8i05oev4nq4m9b848ij07f8c